What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations INDIANAPOLIS -- Eli Lilly is dialing ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes. Much of the ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization north of $800 billion. In the past 12 months, its shares have risen by more than 50% ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their ... to-treat disease," senior vice president of Lilly’s immunology department, Mark Genovese, M.D., said in the company ...

We recently published a list of BofA’s Top 10 Growth Stocks with The Fastest Projected EPS Growth Rates. In this article, we ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...